Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study.
Deodhar A, Blanco R, Dokoupilová E, Hall S, Kameda H, Kivitz AJ, Poddubnyy D, van de Sande M, Wiksten AS, Porter BO, Richards HB, Haemmerle S, Braun J. Deodhar A, et al. Among authors: haemmerle s. Arthritis Rheumatol. 2021 Jan;73(1):110-120. doi: 10.1002/art.41477. Epub 2020 Nov 24. Arthritis Rheumatol. 2021. PMID: 32770640 Free PMC article. Clinical Trial.
Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5.
Huang F, Sun F, Wan WG, Wu LJ, Dong LL, Zhang X, Kim TH, Sengupta R, Šenolt L, Wang Y, Qiu HM, Porter B, Haemmerle S. Huang F, et al. Among authors: haemmerle s. Chin Med J (Engl). 2020 Nov 5;133(21):2521-2531. doi: 10.1097/CM9.0000000000001099. Chin Med J (Engl). 2020. PMID: 32925287 Free PMC article. Clinical Trial.
Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT.
Braun J, Blanco R, Marzo-Ortega H, Gensler LS, van den Bosch F, Hall S, Kameda H, Poddubnyy D, van de Sande M, Wiksten AS, Porter BO, Shete A, Richards HB, Haemmerle S, Deodhar A. Braun J, et al. Among authors: haemmerle s. Arthritis Res Ther. 2021 Sep 4;23(1):231. doi: 10.1186/s13075-021-02613-9. Arthritis Res Ther. 2021. PMID: 34481517 Free PMC article. Clinical Trial.
Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study.
Sigurgeirsson B, Kircik L, Nemoto O, Mikazans I, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB. Sigurgeirsson B, et al. Among authors: haemmerle s. J Eur Acad Dermatol Venereol. 2014 Aug;28(8):1127-9. doi: 10.1111/jdv.12343. Epub 2013 Dec 13. J Eur Acad Dermatol Venereol. 2014. PMID: 24330415 Clinical Trial. No abstract available.
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB. Papp KA, et al. Among authors: haemmerle s. Br J Dermatol. 2013 Feb;168(2):412-21. doi: 10.1111/bjd.12110. Epub 2013 Jan 18. Br J Dermatol. 2013. PMID: 23106107 Clinical Trial.
Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis.
Mallon AM, Häring DA, Dahlke F, Aarden P, Afyouni S, Delbarre D, El Emam K, Ganjgahi H, Gardiner S, Kwok CH, West DM, Straiton E, Haemmerle S, Huffman A, Hofmann T, Kelly LJ, Krusche P, Laramee MC, Lheritier K, Ligozio G, Readie A, Santos L, Nichols TE, Branson J, Holmes C. Mallon AM, et al. Among authors: haemmerle s. BMC Med Res Methodol. 2021 Nov 14;21(1):250. doi: 10.1186/s12874-021-01409-4. BMC Med Res Methodol. 2021. PMID: 34773974 Free PMC article.
14 results